Enhancing preclinical drug discovery with artificial intelligence
- PMID: 34838731
- DOI: 10.1016/j.drudis.2021.11.023
Enhancing preclinical drug discovery with artificial intelligence
Abstract
Artificial intelligence (AI) is becoming an integral part of drug discovery. It has the potential to deliver across the drug discovery and development value chain, starting from target identification and reaching through clinical development. In this review, we provide an overview of current AI technologies and a glimpse of how AI is reimagining preclinical drug discovery by highlighting examples where AI has made a real impact. Considering the excitement and hyperbole surrounding AI in drug discovery, we aim to present a realistic view by discussing both opportunities and challenges in adopting AI in drug discovery.
Keywords: Artificial intelligence; Deep learning; Drug discovery; Machine learning.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that might be perceived as affecting the perception of this review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
